{
    "clinical_study": {
        "@rank": "125966", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Lipoic acid plus omega-3 fatty acids", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary aim of the pilot study is to provide data that can be used to better determine\n      sample size for the design of a larger clinical trial. The pilot will evaluate the\n      effectiveness of Lipoic Acid (LA) plus Omega-3 fatty acids (Omega-3) on preventing\n      Alzheimer's Disease (AD). The investigators will also collect data to evaluate recruitment\n      rate, safety, and compliance over the 12 month study period."
        }, 
        "brief_title": "Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Treated Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "The primary aim is to collect data so that we can determine effect size between lipoic acid\n      plus omega-3 fatty acids and placebo on the primary outcome measure Trails B (executive\n      function). This is designed as a pilot randomized, double-blind, placebo-controlled study\n      with a 12 month intervention period. Thirty participants diagnosed with hypertension that is\n      treated (systolic blood pressure 90-160 mm Hg, diastolic blood pressure 60-90 mm Hg) that\n      have low omega-3 fatty acid levels, and normal cognitive function will be randomized to\n      receive study drug or placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  55 years or older\n\n          -  Non-demented: Montreal Cognitive Assessment > 26 and Clinical Dementia Rating = 0\n\n          -  Diagnosis of Essential Hypertension with systolic 90-160 mm Hg and diastolic 60-90 mm\n             Hg\n\n          -  Stable dose of antihypertensive medication 4 month prior to study enrollment\n\n          -  Stable dose of lipid lowering medication - dose must be stable for 4 months prior to\n             study enrollment\n\n          -  Low Omega-3 fatty acid Status: Omega-3 index, < 4% of total fatty acid of combined\n             docsahexanoic acid and eicosapentanoic acid\n\n          -  Geriatric Depression Scale < 5\n\n          -  General health status that will not interfere with the participant's ability to\n             complete the study.\n\n          -  Screening laboratory values within normal limits or, if abnormal, deemed clinically\n             insignificant by the investigator\n\n          -  Sufficient English language skills to complete all testing\n\n        Exclusion Criteria:\n\n          -  Alzheimer's, Dementia or other neurodegenerative disease.\n\n          -  Health conditions such as cancer diagnosed < 5 years prior to enrollment  (prostate\n             cancer gleason grade < 3 and non metastatic skin cancers are acceptable), liver\n             disease, history of ventricular fibrillation or ventricular tachycardia, major\n             psychiatric disorder, central nervous system diseases (e.g. brain tumor, seizure\n             disorder)\n\n          -  Insulin dependent diabetes or uncontrolled diabetes (diabetes controlled on\n             medications other than insulin are acceptable)\n\n          -  Fish intake of one 6 ounce serving > once a week less than 4 months prior to\n             enrollment\n\n          -  Omega-3 fatty acid supplement intake (e.g. fish oil capsules, cod liver oil) less\n             than 4 months prior to enrollment\n\n          -  Lipoic Acid supplementation less than 1 month prior to enrollment\n\n          -  Taking systemic corticosteroids, neuroleptics, antiparkinsonian agents, and/or\n             narcotic analgesics. Low dose sinemet and dopamine agonist taken once a day for\n             restless leg syndrome is not an exclusion.\n\n          -  Contraindications to MRI, including: subjects with intrathecal pumps, stimulators,\n             pacemakers, aneurysm clips, non-removable hearing aids, or metal fragments in the\n             eyes. Other exclusion criteria include the inability to lie flat on the back for 40\n             minutes at a time or a self-reported history of claustrophobia. Subjects with a\n             history of hip replacement and those with well-documented, verifiable, MRI-safe\n             cardiac stents will not be excluded from the study.\n\n          -  Enrollment in another treatment study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780974", 
            "org_study_id": "SFF01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Lipoic acid plus omega-3 fatty acids"
            ], 
            "description": "alpha lipoic acid (racemic) and fish oil concentrate", 
            "intervention_name": "Lipoic Acid plus Omega-3 Fatty Acids", 
            "intervention_type": "Drug", 
            "other_name": [
                "alpha lipoic acid", 
                "thiotic acid", 
                "fish oil concentrate", 
                "fish oil"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Thioctic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hypertension", 
            "Vascular Risk", 
            "Alzheimer's Risk", 
            "fish oil", 
            "Lipoic acid"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "thompand@ohsu.edu", 
                    "last_name": "Andie Thompson, BA", 
                    "phone": "503-494-7240"
                }, 
                "contact_backup": {
                    "email": "borgatti@ohsu.edu", 
                    "last_name": "Alena Borgatti, BA", 
                    "phone": "503-494-7798"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Lynne Shinto, ND, MPH"
                }, 
                "investigator": {
                    "last_name": "Lynne Shinto, ND, MPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "frasean@ohsu.edu", 
                    "last_name": "Andy Fraser, BS", 
                    "phone": "503-494-7240"
                }, 
                "contact_backup": {
                    "email": "shintol@ohsu.edu", 
                    "last_name": "Lynne Shinto, ND, MPH", 
                    "phone": "503-494-5035"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }, 
                "investigator": {
                    "last_name": "Lynne Shinto, ND, MPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention", 
        "overall_contact": {
            "email": "thompand@ohsu.edu", 
            "last_name": "Andie Thompson, BA", 
            "phone": "503-494-7240"
        }, 
        "overall_contact_backup": {
            "email": "borgatti@ohsu.edu", 
            "last_name": "Alena Borgatti, BA", 
            "phone": "503-494-7798"
        }, 
        "overall_official": {
            "affiliation": "Oregon Health and Science University", 
            "last_name": "Lynne Shinto, ND, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be measured at 6 months and 12 months", 
            "measure": "Trails Making Test Part B (executive function)", 
            "safety_issue": "No", 
            "time_frame": "baseline to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780974"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Oregon Health and Science University", 
            "investigator_full_name": "Lynne Shinto", 
            "investigator_title": "Associate Professor, Department of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "white matter hyperintensity volume (brain MRI)", 
            "safety_issue": "No", 
            "time_frame": "baseline to 12 months"
        }, 
        "source": "Oregon Health and Science University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oregon Health and Science University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}